Into the bargain we cannot know whether patients with new diabetes drugs such as SGLT-2 inhibitors or GLP-1 analogues would have similar or unrelated remission rates, because during the years in which these patients (2001-2009) were included, these drugs were not available in Spain. The gene discussed is SLC5A2; the disease is diabetes mellitus.